Search company, investor...

Compare Fate Therapeutics vs Kardia Therapeutics

Customers evaluate the quality of Fate Therapeutics's products using the following success metrics.

Overview

Fate Therapeutics is 17 yrs old and is based in United States.

Fate Therapeutics (NASDAQ: FATE) is a biotechnology company developing stem cell modulators (SCMs), biologic or small molecule compounds that guide cell fate, to treat patients with very few therapeutic options. Fate Therapeutics' lead clinical program, ProHema, consists of pharmacologicallyenhanced hematopoietic stem cells (HSCs) designed to improve HSC support during the normal course of a stem cell transplant for the treatment of patients with hematologic malignancies. The Company is also advancing a pipeline of human recombinant proteins, each with mechanisms of action, for skeletal muscle, beta-Aislet cell, and post-Aischemic tissue regeneration. Fate Therapeutics also applies its induced pluripotent stem cell (iPSC) technology to offer a highly efficient platform to recapitulate human physiology for commercial scale drug discovery and therapeutic use.

Kardia Therapeutics

Kardia Therapeutics, Inc. is a research-stage biotechnology company focused on the development of cardiac regenerative therapies in the areas myocardial infarction and heart failure. Kardia Therapeutics' portfolio of technologies aims to utilize three related approaches: 1) Adult Cardiac Progenitor Cells, 2) Stem Cell Optimization Technologies, and 3) Homing/Growth Factor Therapies. Because the heart has a limited capacity for self-regeneration, Kardia's technologies have the potential to offer improved patient outcomes compared to existing treatments.

Founded Year